Chronic Lymphocytic Leukemia Stocks List

Recent Signals

Date Stock Signal Type
2021-04-12 AFMD Jack-in-the-Box Bullish Bullish Swing Setup
2021-04-12 BIIB MACD Bearish Centerline Cross Bearish
2021-04-12 BIIB 180 Bearish Setup Bearish Swing Setup
2021-04-12 BIIB Stochastic Reached Oversold Weakness
2021-04-12 CLLS Bollinger Band Squeeze Range Contraction
2021-04-12 EBS Lower Bollinger Band Walk Weakness
2021-04-12 EGRX MACD Bullish Signal Line Cross Bullish
2021-04-12 GMAB Bollinger Band Squeeze Range Contraction
2021-04-12 IMGN Lower Bollinger Band Walk Weakness
2021-04-12 LGND MACD Bearish Signal Line Cross Bearish
2021-04-12 TEVA Bollinger Band Squeeze Range Contraction
2021-04-12 TEVA MACD Bearish Centerline Cross Bearish
2021-04-12 TEVA Stochastic Reached Oversold Weakness
2021-04-12 TEVA NR7-2 Range Contraction
2021-04-12 TEVA NR7 Range Contraction

Recent News for Chronic Lymphocytic Leukemia Stocks

Date Stock Title
Apr 13 EBS EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. is Investigating Emergent BioSolutions, Inc. on Behalf of Emergent Stockholders and Encourages Investors to Contact the Firm
Apr 12 BIIB Neurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogen
Apr 12 BIIB Biogen and Sage trade lower despite positive essential tremor trial
Apr 12 BIIB Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out
Apr 12 BIIB Sage Stock Trips As Analysts Question Longevity Of Biogen-Partnered Drug
Apr 12 AFMD Company News for Apr 12, 2021
Apr 12 GMAB Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review
Apr 12 BIIB Sage Therapeutics/Biogen's SAGE-324 meets primary endpoint in essential tremor study
Apr 12 BIIB Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Apr 12 AFMD Affimed shares gain 5% on encouraging AFM24 data in EGFR-expressing solid tumors
Apr 12 AFMD Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting I
Apr 12 AFMD 51 Biggest Movers From Friday
Apr 10 AFMD The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Apr 10 IMGN ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting
Apr 9 BIIB Biogen Announces Two New Nominees for Election to Board of Directors
Apr 9 GMAB FDA accepts Genmab, Seagen's tisotumab vedotin BLA application for review
Apr 9 GMAB Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Apr 9 AFMD Here's Why Shares of Affimed Skyrocketed Today
Apr 9 AFMD Mid-Afternoon Market Update: Dow Surges Over 100 Points; Provention Bio Shares Plunge
Apr 9 EBS Johnson & Johnson's COVID-19 Vaccine Under Review At EMA For Blood Clots, AstraZeneca Probe Expanded

Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Early on there are typically no symptoms. Later non-painful lymph nodes swelling, feeling tired, fever, or weight loss for no clear reason may occur. Enlargement of the spleen and anemia may also occur. It typically worsens gradually.Risk factors include having a family history of the disease. Exposure to Agent Orange and certain insecticides might also be a risk. CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. These cells do not function well and crowd out healthy blood cells. CLL is divided into two main types: those with a mutated IGHV gene and those without. Diagnosis is typically based on blood tests finding high numbers of mature lymphocytes and smudge cells.Management of early disease is generally with watchful waiting. Infections should more readily be treated with antibiotics. In those with significant symptoms, chemotherapy or immunotherapy may be used. The medications fludarabine, cyclophosphamide, and rituximab are typically the initial treatment in those who are otherwise healthy.CLL affected about 904,000 people globally in 2015 and resulted in 60,700 deaths. The disease most commonly occurs in people over the age of 50. Males are affected more often than females. It is much less common in people from Asia. Five-year survival following diagnosis is approximately 83% in the United States. It represents less than 1% of deaths from cancer.

More about Chronic Lymphocytic Leukemia
Browse All Tags